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Abstract
Objective: To evaluate the influence of the mtDNA haplogroups on knee osteoarthritis progression in Osteoarthritis
Initiative (OAI) participants through longitudinal data from radiographs and magnetic resonance imaging (MRI).
Methods: Four-year knee osteoarthritis progression was analyzed as increase in Kellgren and Lawrence (KL) grade, in
addition to increase in OARSI atlas grade for joint space narrowing (JSN), osteophytes and subchondral sclerosis in the tibia
medial compartment of 891 Caucasian individuals from the progression subcohort. The influence of the haplogroups on the
rate of structural progression was also assessed as the four-year change in minimum joint space width (mJSW in millimetres)
in both knees of (n = 216) patients with baseline unilateral medial-tibiofemoral JSN. Quantitative cartilage measures from
longitudinal MRI data were those related to cartilage thickness and volume with a 24 month follow-up period (n = 381).
Results: During the four-year follow-up period, knee OA patients with the haplogroup T showed the lowest increase in KL
grade (Hazard Risk [HR] = 0.499; 95% Confidence Interval [CI]: 0.261–0.819; p,0.05) as well as the lowest cumulative
probability of progression for JSN (HR = 0.547; 95% CI: 0.280–0.900; p,0.05), osteophytes (HR = 0.573; 95% CI: 0.304–0.893;
p,0.05) and subchondral sclerosis (HR = 0.549; 95% CI: 0.295–0.884; p,0.05). They also showed the lowest decline in mJSW
(standardized response means (SRM) = 20.39; p = 0.037) in those knees without baseline medial JSN (no-JSN knees).
Normalized cartilage volume loss was significantly lower in patients carrying the haplogroup T at medial tibia femoral
(SRM = 20.33; p = 0.023) and central medial femoral (SRM = 20.27; p = 0.031) compartments. Cartilage thickness loss was
significantly lower in carriers of haplogroup T at central medial tibia-femoral (SRM = 20.42; p = 0.011), medial tibia femoral
(SRM = 20.32; p = 0.018), medial tibia anterior (SRM = +0.31; p = 0.013) and central medial femoral (SRM = 20.19; p = 0.013)
compartments.
Conclusions: Mitochondrial genome seems to play a role in the progression of knee osteoarthritis. mtDNA variation could
improve identification of patients predisposed to faster or severe progression of the disease.
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Introduction
Osteoarthritis (OA), the most common joint disease related to
ageing, is characterized by the degeneration of articular cartilage,
affecting subchondral bone and soft tissue and leading to joint
destruction and severe impairment of mobility [1]. OA is also the
leading cause of permanent work incapacitation and one of the
most common reasons for visiting primary care physicians. OA is a
multifactorial disease in which a combination of both environ-
mental and genetic factors interact [2–4].
At present, therapies available to treat OA are limited. Most
current treatments are designed only to relieve pain and reduce or
prevent the disability caused by bone and cartilage degeneration.
Furthermore, clinical testing of new therapies is complicated by
the highly variable way OA manifests in individual patients; it is
established that some OA patients remain relatively stable over
time, while others progress more rapidly to severe structural
deterioration often leading to joint replacement. The usefulness of
both genetic and protein biomarkers in OA is to predict, not only
the risk of OA at an earlier stage of the disease [5], but also which
OA patients are more likely to progress to severe disease. Some
studies have evaluated the role of genetic factors in the severity or
progression of OA [6–9] and, to date, relatively little is known
about risk factors for radiographic knee OA progression, despite
their great clinical importance.
The Osteoarthritis Initiative (OAI) is a public-private partner-
ship that provides new resources and commitment to help find
biochemical, genetic and imaging biomarkers for onset and
progression of knee OA. One of the important goals of the OAI
is to support development and validation of imaging and
biochemical markers that indicate either the presence of OA, or
an increased risk for OA, even when radiograph changes are
minimal or absent, and which can accurately predict the
subsequent course of disease. An essential step to achieve these
goals is the assessment of biomarkers in longitudinal studies, over a
period of time in which clinical change can be clearly defined, in
large, well-characterized populations of persons with OA or who
are developing OA.
The OAI cohort study has a public archive of data, biological
samples and joint images collected over time from a clinically well
characterized population of individuals comprising two subgroups,
i) those with clinically significant knee OA who are at risk of
disease progression; and ii) individuals who are at high risk for
developing clinically significant knee OA. Participants are followed
for four years for changes in the clinical status of the knee and
other joints, including worsening and onset of symptoms and
disabilities, worsening and onset of knee structural abnormalities,
and changes in other imaging and biochemical markers of knee
OA. Therefore, the use of this cohort of samples confers an extra
degree of exceptionality to this work.
In recent years, a growing body of evidence suggests the
implication of the mitochondria in the pathogenesis of OA [1,10–
12]; mitochondrial function is altered in OA chondrocytes [13]
and the mitochondrial dysfunction increases inflammatory re-
sponsiveness to cytokines in normal human chondrocytes [14,15].
Besides, the apoptotic mitochondrial pathway is one of the major
cellular pathways for apoptosis of OA chondrocytes [16] and the
inhibition of complexes III and V of the mitochondrial respiratory
chain (MRC) causes an increased inflammatory response poten-
tially related to the production of reactive oxygen species (ROS)
[14]. Mitochondrial free radical production compromises chon-
drocyte function [17,18], causing mtDNA damage and reduced
mtDNA capacity for repair [19].
In addition to mitochondrial dysfunction, mitochondrial genet-
ics seems to play a role in the OA disease too. Mitochondrial DNA
(mtDNA) haplogroups, defined as individual groups characterized
by the presence of a particular set of single nucleotide polymor-
phisms (SNPs) in the mtDNA sequence [20], have been shown to
be related to OA at different levels: i) prevalence of the disease in
Spanish [6,21] and Asian [22] populations; ii) complementary
genetic markers for the serum levels of collagen type II molecular
biomarkers [23] and proteolytic enzymes [24]; and iii) lower nitric
oxide (NO) production in human articular chondrocytes as well as
higher telomere length [25].
In consideration of this background and the discovery of the
role of mitochondria in OA, the aim of this study is to evaluate the
occurrence of the mtDNA haplogroups in the progression of knee
OA. For this purpose, we used the longitudinal data obtained from
radiographs and magnetic resonance images (MRI) of knee OA
patients belonging to the progression subcohort of the OAI.
Materials and Methods
Data used in the preparation of this article were obtained from
the Osteoarthritis Initiative (OAI) database, which is available for
public access at http://www.oai.ucsf.edu/. The Osteoarthritis
Initiative (OAI) is a public-private partnership comprised of five
contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260;
N01-AR-2-2261; N01-AR-2-2262) funded by the National Insti-
tutes of Health, a branch of the Department of Health and Human
Services, and conducted by the OAI Study Investigators. Private
funding partners include Pfizer, Inc.; Novartis Pharmaceuticals
Corporation; Merck Research Laboratories; and GlaxoSmith-
Kline. Private sector funding for the OAI is managed by the
Foundation for the National Institutes of Health. The study was
reviewed and approved by Comite Etico de Investigación Clı́nica
de Galicia (Ref# 2008/144). Specific datasets used are the 0.2.2
clinical dataset and 0.6, 1.6, 3.5, 5.3, 5.5, 6.3, 0.5 and 1.5 imaging
datasets.
Participants
DNA from all the participants, provided by the OAI, was
previously isolated from buffy coat from plasma samples. All the
participants analyzed in this study (N = 891) were of Caucasian
ancestry and belonged to the progression subcohort of the OAI
(Table 1). This subcohort includes patients with symptomatic
tibiofemoral knee OA at baseline with frequent knee symptoms
(pain, aching or stiffness) and radiographic tibiofemoral knee OA
defined as tibiofemoral osteophytes (OARSI atlas grades 1–3 [26],
equivalent to Kellgren and Lawrence (KL) grade $2) on the fixed
flexion radiographs.
The follow-up period was 48 months for radiographic data and
24 months for magnetic resonance imaging (MRI) data.
All the clinical centers of the OAI have made provisions to
ensure the safety, confidentiality and ethical treatment of study
participants according to the Declaration of Helsinki. In this sense,
all the OAI participants signed an informed consent.
mtDNA haplogroups genotyping
The mtDNA haplogroups of all OA patients were assessed
following DNA isolation using a previously described assay [6].
Briefly, a multiplex polymerase chain reaction (PCR) was
performed to amplify six mtDNA fragments that contain each of
the informative SNPs that characterize the most common
European mtDNA haplogroups (H, V, HV*, Uk, J and T). The
resulting PCR fragments were further purified and analyzed by the
Single Base Extension (SBE) assay and the informative SNPs were
mtDNA Haplogroups Influence OA Progression
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visualized after loading the purified SBE product into an ABI 3130
XL genetic analyzer (Applied Biosystems, Foster City, CA, United
States). The less common haplogroups (W, I, X and others) were
assessed using PCR-restriction fragment length polymorphism
(RFLP) according to the hierarchical scheme previously described
[6]. The assigned mtDNA haplogroups were verified by sequenc-
ing the entire mtDNA control region in 30% of the samples and
analysing some of the key SNPs described in phylotree (http://
www.phylotree.org).
Progression criteria
We analyzed radiographic knee OA progression during the
follow-up period (48 months) in terms of the KL grade, defining
progression as an increase of at least one KL grade in either knee.
Additionally, we also analyzed the development or progression of
i) joint space narrowing in the medial compartment (mJSN), ii)
osteophytes in the tibia medial compartment and iii) subchondral
sclerosis in the tibia medial compartment. The progression
criterion for each of these three features was an increase of at
least one OARSI atlas grade in either knee.
Table 1. Demographic characteristics of the study population at baseline grouped by mitochondrial DNA (mtDNA) haplogroups in
the progression subcohort of the OAI.
mtDNA haplogroups
Characteristic
H (N = 341,
38.27%)
J (N = 89,
9.99%)
T (N = 85,
9.54%)







Age at baseline (years) 62.269.1 60.369.9 61.669.5 62.469.5 61.469.6 0.378* 61.969.4
Gender: 0.792#
Male 164 (48.1) 41 (46.1) 45 (52.9) 111 (48.7) 66 (44.6) 427 (47.9)
Female 177 (51.9) 48 (53.9) 40 (47.1) 117 (51.3) 82 (55.4) 464 (52.1)
BMI (Kg/m2) 29.664.5 29.664.8 29.664.5 29.264.9 29.264.4 0.596* 29.464.6
BMI#30 192 (56.3) 50 (56.2) 50 (58.8) 138 (60.5) 92 (62.2) 0.721# 522 (58.6)
BMI.30 149 (43.7) 39 (43.8) 35 (41.2) 90 (39.5) 56 (37.8) 369 (41.4)
KL grade at baseline (worst knee)** 0.851#
0–I 45 (14.0) 9 (10.8) 9 (11.3) 31 (14.8) 21 (14.9) 115 (13.8)
II–IV 277 (86.0) 74 (89.2) 71 (88.8) 179 (85.2) 120 (85.1) 721 (86.2)
KL grade at baseline (less severe knee) 0.538#
0–I 142 (44.1) 39 (47.0) 34 (42.5) 105 (50.0) 71 (50.4) 391 (46.8)
II–IV 180 (55.9) 44 (53.0) 46 (57.5) 105 (50.0) 46 (57.5) 445 (53.2)
mJSN at baseline (worst knee) 0.777#
0–I 179 (55.6) 43 (51.8) 46 (57.5) 113 (53.8) 84 (59.6) 465 (55.6)
II–III 143 (44.4) 40 (48.2) 34 (42.5) 97 (46.2) 57 (40.4) 371 (44.4)
mJSN at baseline (less severe knee) 0.885#
0–I 280 (87.0) 73 (88.0) 67 (83.8) 180 (85.7) 119 (84.4) 719 (86.0)
II–III 42 (13.0) 10 (12.0) 13 (16.3) 30 (14.3) 22 (15.6) 117 (14.0)
Osteophytes tibia medial (worst knee) 0.046#
0–I 192 (67.4) 39 (52.7) 41 (56.9) 107 (57.5) 82 (66.7) 461 (62.3)
II–III 93 (32.6) 35 (47.3) 31 (43.1) 79 (42.5) 41 (33.3) 279 (37.7)
Osteophytes tibia medial (less severe knee) 0.577#
0–I 267 (93.7) 68 (91.9) 66 (91.7) 174 (93.5) 119 (96.7) 694 (93.8)
II–III 18 (6.3) 6 (8.1) 6 (8.3) 12 (6.5) 4 (3.3) 46 (6.2)
Sclerosis tibia medial (worst knee) 0.131#
0–I 181 (63.5) 37 (50.0) 46 (63.9) 110 (59.1) 83 (67.5) 457 (61.8)
II–III 104 (36.5) 37 (50.0) 26 (36.1) 76 (40.9) 40 (32.5) 283 (38.2)
Sclerosis tibia medial (less severe knee) 0.494#
0–I 268 (94.0) 66 (89.2) 65 (90.3) 168 (90.3) 112 (91.1) 679 (91.8)
II–III 17 (6.0) 8 (10.8) 7 (9.7) 18 (9.7) 11 (8.9) 61 (8.2)
Values are mean6standard deviation or number of patients with percentage in parentheses; OAI: osteoarthritis initiative; (*) Kruskal-Wallis non-parametric test for
comparison between mtDNA haplogroups; (#) Chi-square test; BMI: body mass index; KL: Kellgren and Lawrence; mJSN: Joint space narrowing in medial compartment;
(**) The worst knee and the less severe knee at baseline were designated, respectively, as the knee with the highest and lowest KL (Kellgren andLawrence) grade, OARSI
JSN (joint space narrowing) grade, OARSI osteophytes grade or OARSI sclerosis grade, as appropriate on each case; significant p-values are in bold.
doi:10.1371/journal.pone.0112735.t001
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We also analyzed the influence of the mtDNA haplogroups on
the rate of structural progression in both knees of patients with
baseline unilateral medial JSN (OARSI atlas grade 1–3) and no
JSN in the lateral compartment (OARSI atlas grade ,1). For this
purpose, we analyzed the four-year change in radiographic medial
joint space width (mJSW) at the minimum JSW in the medial
compartment of both knees (baseline JSN knees and baseline no-
JSN knees) of 216 OA patients that met the eligibility criteria.
Description of the MRI data
For this study, we analyzed the data obtained from measure-
ments of cartilage volume and thickness from serial knee MRI
scans performed by Felix Eckstein’s group in Germany (Chondro-
metrics, Gmbh, Ainring) or Austria (Paracelsus University,
Salzburg) (http://www.chondrometrics.com/) and contained in
different datasets (Projects) of the OAI. These data consisted in a
longitudinal study with a 24 month follow-up period of 381 knee
OA patients (190 right knees and 191 left knees) in the progression
subcohort (namely Project 9). We analyzed data from measure-
ments of the femoral region defined as the 75% of the distance
between trochlear notch and the posterior of the femoral condyle
(Figure S1).
The image analysis relied on sagittal DESS (double echo steady-
state) sequence of either the right or left knee [27,28]. Segmen-
tation of the cartilages was performed at the image analysis center
(Chondrometrics GmbH, Ainring, Germany).
Sample size of the study
The sample size of n = 891 patients allows the probability of OA
progression to be estimated with 63.3% precision using a 95%
confidence interval. Additionally, ‘‘protective’’ hazard ratios (HR)
, = 0,6 associated with an haplogroup present in at least 10% of
the population will be detected as statistically significant with 80%
power using a significant level of 0,05. This assumes a censoring
probability of 60%.
To analyze the four-year change in medial JSW in patients with
unilateral medial JSN, n = 216 OA patients were included in the
analysis. Assuming a standard deviation of 61, this sample size
will allow us to detect as statistically significant mean differences of
0.6 or higher for the less frequent haplogroup (n = 24), with 80%
power and a significant level of 0.05
For the analysis of cartilage integrity from MRI, data on n = 381
patients are available. This sample size will allow to detect as
statistically significant a standardized mean difference of 0,35 or
higher in the variables analyzed between the most and the less
frequent haplogroup (assuming a ratio 1:4), with a 95% confidence
level and 80% statistical power.
Statistical analysis
Briefly, for the multivariate analysis of radiographic progression
and MRI data, comparisons between haplogroups were performed
considering the most common mtDNA haplogroup, H, as the
reference group. Therefore, in order to introduce mtDNA
haplogroups in the models, a dummy coding was used, with the
haplogroup H as the reference group. Since there was no interest
in all possible pair-wise comparisons, no additional adjusting for
multiple comparisons was done.
Statistical analyses were performed using IBM-SPSS software,
release 19 (IBM, Armonk, NY, USA) and R software v3.0.2 (The
R Foundation for Statistical Computing). All comparisons were
two-sided, with p,0.05 defined as statistically significant.
Analysis of radiographic progression. Because the status
of a patient was prospectively evaluated at predefined intervals (12,
24, 36 and 48 months), the precise date at which progression
occurred could not be determined; it always occurred between
visits. Only the interval during which the conversion occurred was
observed, therefore such information is said to be interval-
censored [29].
To avoid potential biases associated with the use of standard
survival analysis in this context, interval-censored data analysis
methods were used [29]. Turnbull’s extension of the Kaplan-
Meier curve to interval-censored data was used to estimate the
cumulative probability of progression over time (survivor function)
according to the mtDNA haplogroups [30]. An extended Cox
proportional hazard model using the iterative convex minorant
algorithm was used for multivariate analysis adjusting for the
confounder effects of gender, age, BMI, radiographic status of the
worst knee (highest KL grade, highest JSN OARSI grade, highest
osteophytes OARSI grade or highest sclerosis OARSI grade, as
appropriate on each case) and previous surgery, all of them at
baseline [31]. Due to difficulties in deriving the asymptotic
behavior of statistic tests based on interval-censored data, statistical
significance was tested by confidence intervals (CIs) for the hazard
ratios (HR) by means of resampling methods. Therefore, CIs were
obtained using the bootstrap methodology (1000 replicates) with
the percentile method.
To analyze the influence of the mtDNA haplogroups on four-
year change in medial JSW (mJSW) from baseline, we focused on
patients with unilateral medial JSN and no JSN in the lateral
compartment. The JSN knees and no-JSN knees were modeled
separately. The mean comparison of the difference between
mJSW at baseline and mJSW at final visit (4 years) was further
performed by means of an analysis of covariance (ANCOVA)
comparing each of the mtDNA haplogroups with the rest pooled
together and adjusting for the confounder effects of gender, age
and BMI at baseline. Previously, we tested for possible significant
associations of the mtDNA haplogroups with KL grade and mJSN
at baseline for both JSN and no-JSN knees in this cohort of
(n = 216) patients by means of chi-square analyses. Additionally,
the standardized response means (SRM), defined as the mean
change divided by the standard deviation (SD) of change, was used
to measure the sensitivity to change.
Analysis of MRI data in the OAI cohort. The parameters
analyzed were those related to both cartilage volume and thickness
in representative subregions of the joint (Figure S2). The
parameters for cartilage volume were: cartilage volume in the
medial tibia femoral compartment (MFTC.VC) and central
medial femoral (cMF.VC) and normalized cartilage volume in
the medial tibia femoral compartment (MFTC.VCtAB) and the
central medial femoral (cMF.VCtAB). We also analyzed the mean
cartilage thickness in the central medial tibia femoral compart-
ment (weight bearing) (cMFTC.ThCtAB), medial tibia femoral
compartment (MFTC.ThCtAB), medial tibia (anterior) (aMT.
ThCtAB) and central medial femoral (center) (ccMF.ThCtAB).
The mean change (MC) and standard deviation (SD) of change
between baseline (T0) and 24 months (T2) were used as a measure
of progression. The SRM was used as a measure of sensitivity to
change. The influence of mtDNA haplogroups on changes over
time in quantitative MRI scans data, between T0 and T2, was
evaluated though a linear mixed-effects random-intercept and
random-slope repeated measures analysis [32]. This model
assumes that patient effects (intercepts) and time effects (slopes—
MRI data changes over time) are random among patients, taking
into account the correlation among repeated measurements in the
same individual. Regression coefficients were also estimated for the
interaction between time and mtDNA haplogroup, allowing the
rate of change to vary from one haplogroup to another. Models
mtDNA Haplogroups Influence OA Progression












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































mtDNA Haplogroups Influence OA Progression
PLOS ONE | www.plosone.org 5 November 2014 | Volume 9 | Issue 11 | e112735
were also adjusted for potential confounding factors, including age,
gender and BMI.
Results
Influence of the mtDNA haplogroups on radiographic
knee OA progression
No significant differences in baseline characteristics, including
age, gender and BMI of the study population, as well as the
radiographic variables at baseline, were detected among the
different mtDNA haplogroups, even when analyzed the worst knee
and the less severe knee, except for the presence of osteophytes in
the worst knee (p = 0.047) (Table 1). The worst knee and the less
severe knee at baseline were designated, respectively, as the knee
with the highest and lowest KL grade, OARSI JSN grade, OARSI
osteophytes grade or OARSI sclerosis grade, as appropriate on
each case. We then analyzed the increase of KL grade in knee OA
patients as well as the radiographic progression or development of
JSN, osteophytes and subchondral sclerosis.
After adjusting for age, gender, BMI, previous surgery and
radiographic status of the worst knee at baseline, the results
showed that the percentage of patients that experienced any
increase in the KL grade during the follow-up period was
significantly lower in carriers of the mtDNA haplogroup T
(HR = 0.499; 95% CI: 0.261–0.819; p,0.05); in addition, these
patients also showed less development of JSN (HR = 0.547; 95%
CI: 0.280–0.900; p,0.05), osteophytes (HR = 0.573; 95% CI:
0.304–0.893; p,0.05) and subchondral sclerosis (HR = 0.549;
95% CI: 0.295–0.884; p,0.05) (Table 2).
BMI at baseline was found to be a risk factor for radiographic
progression (p,0.05) in terms, not only of KL grade (HR = 1.045;
95% CI: 1.020 – 1.069), but also JSN (HR = 1.052; 95% CI:
1.021–1.084) and osteophytes (HR = 1.028; 95% CI: 1.004–1.055)
besides, radiographic status of worst knee at baseline significantly
associates (p,0.05) with increased development of JSN
(HR = 4.993; 95% CI: 3.700–7.373), osteophytes (HR = 1.799;
95% CI: 1.405–2.314) and sclerosis (HR = 1.396; 95% CI: 1.050–
1.827) during the follow-up period; male gender was also
associated with lower risk for disease progression (p,0.05) in
terms of KL grade (HR = 0.672; 95% CI: 0.528–0.859) (Table 2).
The analysis of the influence of the mtDNA haplogroups on the
rate of structural progression in no-JSN knees, assessed by means
of the minimum mJSW, showed carriers of the mtDNA
haplogroup T with the lowest decline over time (SRM = 20.39;
p = 0.037) (Table 3). Additionally, no significant differences were
detected in KL grade and mJSN at baseline, in both JSN and no-
JSN knees, among the mtDNA haplogroups in this cohort of 216
patients (data not shown).
Influence of the mtDNA haplogroups on knee cartilage
integrity. Data from MRI
Longitudinal analysis of cartilage volume. A significant
decline in knee cartilage volume over time was detected
(p,0.001). Patients that carry the mtDNA haplogroup T showed
significantly lower declines in volume over time in medial tibia
femoral (p = 0.015) (MC = 20.02610360.12 mm3) and central
medial femoral (p = 0.015) (MC = 20.01610360.08 mm3) com-
partments compared with the most common mtDNA haplogroup
H (MC = 20.11610360.25 mm3 and 20.07610360.15 mm3,
respectively). When the normalized cartilage volume (cartilage
volume divided by total area of subchondral bone) of these two
subregions was analyzed, the results obtained were similar and
carriers of the mtDNA haplogroup T also showed significantly
lower declines in normalized volume in medial tibia femoral
(p = 0.023) (MC = 20.0460.12 mm) and central medial femoral
(p = 0.031) (MC = 20.0360.10 mm) compartments (MC = 2
0.1260.25 mm and 20.0860.18 mm, respectively) (Figure 1a,
Table 4 and Table S1). No differences were found in the rate of
change between mtDNA haplogroup H and the other mtDNA
haplogroups.
Longitudinal analysis of cartilage thickness. A significant
decline in cartilage thickness over time was observed (p,0.001).
When compared with carriers of mtDNA haplogroup H, patients
with haplogroup T had significantly lower declines in thickness
over time in central medial tibia femoral (weight bearing) (MC =
20.0860.18 mm versus 20.2460.41 mm, p = 0.011), medial
tibia femoral (MC = 20.0460.12 mm versus 20.1360.26 mm,
p = 0.018), medial tibia (anterior) (MC = +0.0260.08 mm versus
20.0260.10 mm, p = 0.013) and central medial femoral (center)
(MC = 20.0360.14 mm versus 20.1360.29 mm, p = 0.013)
compartments (Figure 1b, Table 4 and Table S1). Similar to
cartilage volume, no differences in the loss rate of knee cartilage
thickness over time were detected between mtDNA haplogroup H
and the other haplogroups.
Discussion
To our knowledge, this is the first study to use the well
characterized follow-up OAI cohort to analyze the influence of
genetic factors on disease progression. Specifically, this study
attempts to analyze the influence of mtDNA haplogroups on the
progression of knee OA. The results obtained reveal that patients
Table 3. Mean differences in mJSW change over 4 years at minimum mJSW among the mitochondrial DNA (mtDNA) haplogroups
in 216 OA patients.
JSN knees (N = 216) No-JSN knees (N = 216)
mtDNA haplogroups Mean change±SD SRM p-value# Mean change±SD SRM p-value#
H (N = 87) 20.5260.68 20.77 0.688 20.5661.07 20.52 0.754
J (N = 24) 20.7560.86 20.87 0.217 20.6260.78 20.79 0.578
T (N = 24) 20.5660.77 20.73 0.919 20.1460.37 20.39 0.034*
Uk (N = 44) 20.5360.68 20.77 0.995 20.6161.12 20.59 0.336
Others (N = 37) 20.4860.68 20.71 0.662 20.4560.65 20.69 0.886
Data are mean6standard deviation, in millimetres (mm); mJSW: medial joint space width; JSN: joint space narrowing; SD: standard deviation; SRM: standardized
response means (mean divided by SD); (#) multivariate (ANCOVA) analysis, adjusting for gender, age and body mass index (BMI) at baseline; (*) indicates statistical
significance at p#0.05.
doi:10.1371/journal.pone.0112735.t003
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in the progression subcohort carrying mtDNA haplogroup T show
not only a significantly lower cumulative probability of progression
in KL grade, but also less development of mJSN, osteophytes and
subchondral sclerosis in the medial tibia. These observations were
further strengthened by analyzing the evolution of cartilage
integrity over two years showing a significantly reduced loss of
knee cartilage thickness and volume in carriers of mtDNA
haplogroup T too.
Previous findings reported in a Spanish cohort showed that
patients with haplogroups belonging to cluster TJ had slower
radiographic OA progression attending to KL grade [33].
Interestingly, an association study between haplogroups and OA
prevalence in Spanish populations revealed a significant overrep-
resentation of the cluster TJ in radiological knee healthy subjects
[6]. This association was further partially replicated in a larger
cohort of hip OA patients from the same location, showing an
association of the mtDNA haplogroup J with lower prevalence of
hip OA [21]. Moreover, in another recent work, the mtDNA
haplogroup T appeared overrepresented in knee healthy subjects
from the United Kingdom after performing a regression model
adjusting for gender and age [34].
To date, the study presented here is the first and most complete
progression study involving the mtDNA haplogroups and OA
using the cohort of the OAI; the results obtained should not be
interpreted as discrepant in relation to previous findings, not only
because this work does not analyze the association of mtDNA
haplogroups with the prevalence of OA, but also because both
above-mentioned mtDNA haplogroups T and J are considered
‘‘sister’’ haplogroups that share the same phylogenetic origin (the
mtDNA cluster TJ) [35,36] that comprises a set of uncoupling
mutations which, in combination with certain nuclear back-
grounds, have been described to have common functional
characteristics in their OXHPOS system such as decreased ATP
production and reduced ROS generation [37–39].
A recent work by Hudson and co-workers found no evidence of
an association between mtDNA variants and the prevalence of OA
[40]. However, some points could explain this; first, as postulated
by the authors, the relative contribution of specific mtDNA
variants could vary in different ethnic groups by means of
homoplasy and/or geographic differences in the finer details of
sub-haplogroup structures of mtDNA [40]. In this sense,
population-specific associations of the mtDNA haplogroups,
probably due to their interaction with environmental factors
[41] as a result of their adaptation to colder climates [35,36,42],
have also been described [43,44]; second, as the authors describe
in their manuscript, the GWAS study performed by the arcOGEN
consortium also failed to replicate previous associations involving
other genes described in OA at genome-wide significance levels,
such as GDF5, chromosome 7q22 and MCF2L [45]; third, control
samples from the arcOGEN study are only asymptomatic with no
radiographic information, thus the selection of adequate healthy
controls for association studies in the OA disease is a crucial for
successfully conclusions.
The risk of structural progression in a knee without baseline JSN
(no-JSN knee) is higher when the contralateral knee has already
lost some space (JSN-knee); therefore, some authors suggest that
the no-JSN knee would be the target knee in clinical trials because
it would be expected to have less damage than a JSN knee but may
have a significant progression over time due to the prevalence of
contralateral JSN [46,47]. In order to evaluate the feasibility of
detecting drug effects in clinical trials, we have quantified the
mJSW following a similar approach to that described by Benichou
and co-workers [48]. Results showed that OA patients with the
mtDNA haplogroup T had lower rate of structural progression in
no-JSN knees. These results point to take into consideration the
mtDNA haplogroups when clinical trials in this population are
performed.
The medial compartment is generally heavily loaded and knee
OA affects this compartment more often than the lateral one
[49,50]; therefore the analysis of MRI images carried out in this
work was performed in regions/subregions that were previously
characterized among the most sensitive to change in knee OA: the
central medial tibia femoral compartment and medial tibia
femoral compartment [28,51–54], as well as other regions of
interest such as the central medial femoral condyle and medial
tibia (anterior). The conclusion drawn is that OA patients carrying
the mtDNA haplogroup T had a significantly lower decline of
cartilage thickness and volume over time in these medial
subregions.
A key part of the variation in different clinical forms of OA is
attributable to genetics [55]. In relation to OA progression,
previous studies by other investigators reported that genetic
variants of genes, such as interleukin-1 receptor antagonist
(IL1RN) [9,56,57] or cartilage intermediate-layer protein (CILP)
[7], influence the severity and progression of OA. A functional
polymorphism in the 59-UTR of the growth differentiation factor-
5 (GDF-5) gene has also been consistently associated with OA
susceptibility and was part of a prediction model for knee OA
based on genetic and clinical information [58,59]. The results of
the present study strengthen the role of genetic variation, including
mitochondrial genetics, in OA as previously described [1,3].
This study has some points that must be clarified; i) in relation
to confounding factors, the analyses were finally adjusted for
potential confounders such as age, gender, BMI and, in the
radiographic progression, previous surgery and the radiographic
status of the worst knee at baseline. Other predictors of OA
occurrence or progression over time, such as bone marrow lesions
or meniscal lesions, were also analyzed but finally not taken into
account because of the small number of patients without missing
data. On the other hand, ii) a key strength of this study is the
analysis performed; the use of interval-censored data analysis to
determine the probability of knee OA progression according to the
mtDNA haplogroups avoids biases associated with the use of
standard survival analysis in this context. Moreover, the use of
linear mixed models in the analysis of MRI data allows us to take
into account all available observations for each patient over time,
Figure 1. Figure 1a. Longitudinal change between baseline and 24 months in cartilage volume grouped by mitochondrial DNA
(mtDNA) haplogroups. MFTC.VCtAB: normalized cartilage volume in medial tibia femoral compartment; cMF.VCtAB: normalized cartilage volume
in central medial femoral; MFTC.VC: cartilage volume in medial tibia femoral compartment; cMF.VC: volume of cartilage in central medial femoral.
MFTC.VC and cMF.VC that are shown in cubic millimeters (mm3) and MFTC.VCtAB and cMF.VCtAB are shown in square centimeters (cm2); (*) indicates
statistical significance (p,0.05). Values are mean change+SE (standard error). Figure 1b. Longitudinal change between baseline and 24 months in
cartilage thickness grouped by mitochondrial DNA (mtDNA) haplogroups. cMFTC.ThCtAB: mean cartilage thickness in central medial tibia femoral
compartment (weight-bearing); MFTC.ThCtAB: mean cartilage thickness in medial tibia femoral compartment; aMT.ThCtAB: mean cartilage thickness
in medial tibia (anterior); ccMF.ThCtAB: mean cartilage thickness in central medial femoral (center). All of them represented in millimeters (mm); (*)
indicates statistical significance (p,0.05). Values are mean change+SE (standard error).
doi:10.1371/journal.pone.0112735.g001
mtDNA Haplogroups Influence OA Progression

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































mtDNA Haplogroups Influence OA Progression
PLOS ONE | www.plosone.org 9 November 2014 | Volume 9 | Issue 11 | e112735
therefore providing more accurate results and higher statistical
power.
In summary, the results obtained in this work are of special interest
because they show not only significant smaller longitudinal radio-
graphic changes in patients carrying the mtDNA haplogroup T, but
also significant lower decline in thickness and volume over time in
weight bearing cartilage. A possible physiological explanation for these
results, in line with what it was described above, is the mtDNA
haplogroup T shows higher capacity to cope with oxidative stress than
haplogroup H do [37] and oxidative stress is involved in the
pathogenesis of OA [60]. This differential behavior is probably related
with the origin of the mtDNA haplogroups, which are the result of a
process of adaptive selection that permitted humans to adapt to colder
climates when emigrated out from Africa [35,36]. Based on this theory,
some of these mtDNA variants, specifically the mtDNA haplogroup H,
are highly efficient in transforming the dietary calories into ATP,
generating minimum heat and increased ROS; meanwhile, other
mtDNA variants, such as mtDNA haplogroups T and J, are less
efficient in converting dietary calories into ATP, therefore producing
more heat and less ROS [61]. However, these mtDNA variants that
have been critical for human adaptation to different global environ-
ments (not only temperature, but also changes in food or caloric supply,
seasonal variation in climate or even infections) and would have
favored survival and reproduction of populations residing in a
particular climate zone might be maladaptive in a different
environment with new lifestyles [62]. Hence, mtDNA haplogroups
have been correlated with predisposition to a wide range of metabolic
and degenerative diseases, obesity, cancers and longevity in a
population-specific manner [42,63,64].
In conclusion, the results obtained in this work point to a
possible role of mtDNA variation in the radiographic progression
of OA and could improve identification of patients predisposed to
faster or more severe progression of the disease. If further validated
in additional prospective and well-characterized cohorts, the
inclusion of mtDNA haplogroup assignment may also be useful
for clinical trials.
Supporting Information
Figure S1 Sagittal RM images (DESSwe sequence) with the
cartilage of MF being divided into cMF and pMF at 60% (left) and
75% (right) of the distance between the trochlear notch and the
posterior end of the femoral condyle; MT: medial tibia; MF:
medial femoral condyle; cMF: central (weight bearing) medial
femoral condyle; pMF: posterior medial femoral condyle.
(TIF)
Figure S2 Representative subregions of the knee used to
track changes in cartilage thickness and volume. cMF:
central (weight-bearing) medial femoral condyle; MT: medial
tibia; cLF: central (weight-bearing) lateral femoral condyle; LT:
lateral tibia; ccMF: central subregion of central (weight-bearing)
medial femur; cMFTC: central medial femoro-tibial compart-
ment; cMT: central subregion of medial tibia; aMT: anterior
subregion of medial tibia.
(TIF)
Table S1 Longitudinal change between baseline (T0) and 24
months (T2) in quantitative parameters of cartilage integrity
(volume and thickness) grouped by mitochondrial DNA (mtDNA)
haplogroups.
(DOCX)
Table S2 Cross-sectional differences among the mitochondrial
DNA (mtDNA) haplogroups in quantitative parameters of
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of (n = 326) knee OA patients in the progression subcohort of the
OAI with no follow-up (namely Project 18).
(DOCX)
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